Edition:
United Kingdom

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

137.06USD
9:00pm BST
Change (% chg)

$-2.33 (-1.67%)
Prev Close
$139.39
Open
$141.00
Day's High
$142.33
Day's Low
$133.16
Volume
339,956
Avg. Vol
192,273
52-wk High
$199.35
52-wk Low
$87.64

About

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)

Overall

Beta: 2.03
Market Cap(Mil.): $5,824.04
Shares Outstanding(Mil.): 45.59
Dividend: --
Yield (%): --

Financials

  BLUE.OQ Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -7.36 -- --
ROI: -25.26 8.91 13.83
ROE: -29.40 10.06 15.25

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

29 Mar 2019

UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

29 Mar 2019

EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

29 Mar 2019

Earnings vs. Estimates